Recently, the FDA approved new combinatorial treatments including atezolizumab (PD-L1 inhibitor) in combination with cobimetinib and vemurafenib for patients with BRAFV600 mutation-positive advanced stage melanoma [19]. The gene discussed is CD274; the disease is melanoma.